Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea.
School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
Epidemiol Health. 2024;46:e2024065. doi: 10.4178/epih.e2024065. Epub 2024 Jul 17.
Patients with kidney disease have been prioritized for coronavirus disease 2019 (COVID-19) vaccination due to their susceptibility to COVID-19 infection. However, little evidence exists regarding these patients' vulnerability to COVID-19 post-vaccination. Thus, we evaluated the risk of COVID-19 in patients with kidney disease compared to individuals without kidney disease according to vaccination status.
A retrospective cohort study was conducted using the Korean nationwide COVID-19 registry linked with National Health Insurance Service claims data (2018-2021). Among individuals aged 12 years or older, 2 separate cohorts were constructed: a COVID-19-vaccinated cohort and an unvaccinated cohort. Within each cohort, the risk of COVID-19 infection and all-cause mortality, hospitalization, and emergency room visits within 30 days of COVID-19 infection were compared between patients with and without kidney disease. To adjust for potential confounding, we used propensity score matching. Hazard ratios (HRs) for each outcome were estimated using a Cox proportional hazard model.
We identified 785,390 and 836,490 individuals in the vaccinated and unvaccinated cohorts, respectively. Compared to patients without kidney disease, patients with kidney disease were at a higher risk of COVID-19 infection in both the vaccinated cohort (HR, 1.08; 95% confidence interval [CI], 1.02 to 1.16) and the unvaccinated cohort (HR, 1.09; 95% CI, 0.99 to 1.20). Likewise, patients with kidney disease generally were at higher risk for severe clinical outcomes within 30 days of COVID-19 infection. Subgroup and sensitivity analyses showed generally consistent results.
Our study observed excess risk of COVID-19 in patients with kidney disease, highlighting the importance of ongoing attention to these patients even post-vaccination.
由于肾脏疾病患者易感染 COVID-19,因此他们被优先接种 2019 年冠状病毒病(COVID-19)疫苗。然而,关于这些患者在接种疫苗后对 COVID-19 的易感性,几乎没有证据。因此,我们根据接种疫苗情况评估了与无肾脏疾病患者相比,肾脏疾病患者 COVID-19 的风险。
利用韩国全国 COVID-19 登记系统与国家健康保险服务索赔数据(2018-2021 年)进行了回顾性队列研究。在年龄为 12 岁或以上的个体中,构建了两个单独的队列:COVID-19 接种队列和未接种队列。在每个队列中,比较了有和无肾脏疾病患者 COVID-19 感染的风险以及感染后 30 天内的全因死亡率、住院和急诊就诊。为了调整潜在的混杂因素,我们使用倾向评分匹配。使用 Cox 比例风险模型估计每种结局的风险比(HR)。
我们分别在接种组和未接种组中确定了 785390 名和 836490 名个体。与无肾脏疾病的患者相比,接种组(HR,1.08;95%置信区间[CI],1.02 至 1.16)和未接种组(HR,1.09;95%CI,0.99 至 1.20)中,有肾脏疾病的患者 COVID-19 感染的风险更高。同样,肾脏疾病患者 COVID-19 感染后 30 天内一般具有更高的严重临床结局风险。亚组和敏感性分析得出了大致一致的结果。
我们的研究观察到肾脏疾病患者 COVID-19 的风险增加,这强调了即使在接种疫苗后,仍需要持续关注这些患者。